Literature DB >> 1542792

Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M.

B C Nair1, A L DeVico, S Nakamura, T D Copeland, Y Chen, A Patel, T O'Neil, S Oroszlan, R C Gallo, M G Sarngadharan.   

Abstract

Conditioned medium from human T cell leukemia virus type 2 (HTLV-II)-infected T cells supports the growth and long-term culture of cells derived from acquired immunodeficiency syndrome (AIDS)-associated Kaposi's sarcoma lesions (AIDS-KS cells). A protein of 30 kilodaltons was purified from conditioned medium that supports the growth of AIDS-KS cells. The amino-terminal sequence of this protein was identical to the amino-terminal sequence of Oncostatin M, a glycoprotein that inhibits the growth of a variety of cancer cells. Oncostatin M from conditioned medium stimulated a twofold increase in the growth of AIDS-KS cells at a concentration of less than 1 nanogram of the protein per milliliter of medium.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1542792     DOI: 10.1126/science.1542792

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  42 in total

1.  Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor.

Authors:  Rizwan Masood; Ethel Cesarman; D Lynne Smith; Parkash S Gill; Ornella Flore
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo.

Authors:  C Langdon; C Kerr; M Hassen; T Hara; A L Arsenault; C D Richards
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules.

Authors:  V Modur; M J Feldhaus; A S Weyrich; D L Jicha; S M Prescott; G A Zimmerman; T M McIntyre
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

4.  Oncostatin-M stimulates tyrosine protein phosphorylation in parallel with the activation of p42MAPK/ERK-2 in Kaposi's cells. Evidence that this pathway is important in Kaposi cell growth.

Authors:  M C Amaral; S Miles; G Kumar; A E Nel
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

5.  Oncostatin-M is an autocrine growth factor in Kaposi's sarcoma.

Authors:  J Cai; P S Gill; R Masood; P Chandrasoma; B Jung; R E Law; S F Radka
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

6.  Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells.

Authors:  J Corbeil; E Rapaport; D D Richman; D J Looney
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 7.  Kaposi's sarcoma in HIV infected women in Germany: more evidence for sexual transmission. A report of 10 cases and review of the literature.

Authors:  H Albrecht; E B Helm; A Plettenberg; C Emminger; W Heise; B Schwartländer; H J Stellbrink
Journal:  Genitourin Med       Date:  1994-12

8.  Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells.

Authors:  R K Ganju; N Munshi; B C Nair; Z Y Liu; P Gill; J E Groopman
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  KSHV-induced notch components render endothelial and mural cell characteristics and cell survival.

Authors:  Ren Liu; Xiuqing Li; Anil Tulpule; Yue Zhou; Jeffrey S Scehnet; Shaobing Zhang; Jong-Soo Lee; Preet M Chaudhary; Jae Jung; Parkash S Gill
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

10.  Human immunodeficiency virus-associated oral Kaposi's sarcoma. A heterogeneous cell population dominated by spindle-shaped endothelial cells.

Authors:  J A Regezi; L A MacPhail; T E Daniels; Y G DeSouza; J S Greenspan; D Greenspan
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.